(Holzgerlingen, Germany, October 9, 2012) -- Curetis AG today announced it has
completed enrollment for the European clinical trial of its Unyvero™ Pneumonia
Application on schedule. More than 800 patient samples were collected until
September 30, 2012 in just 7 months. Data analysis will be completed in early 2013.
Subsequently, results will be published in a major, peer-reviewed journal.

The trial will compare the performance of the Unyvero™ P50 Pneumonia Cartridge
with conventional microbiology culture, the current standard of care. Primary endpoint
will be clinical sensitivity and speci? city for the identi? cation of 17 pathogens covered
by the Unyvero™ P50 panel. Secondary endpoints include time to result and
correlation of resistance marker detection with phenotypic antibiograms. Curetis will
conduct systematic discrepant results resolution by PCR and sequencing to con? rm
the clinical truth in samples where Unyvero results differ from microbiology culture.

The study complements the previously completed CE performance evaluation study,
in which the Unyvero P50 Cartridge identi? ed a signi? cant number of additional
pathogens not detected by microbiology culture. These ? ndings were con? rmed by
PCR analysis.

“We are happy to announce the successful completion of another major clinical
project milestone,” said Oliver Schacht, CEO of Curetis. “Together with the more than
200 samples analyzed earlier this year, we now have data collected from over 1,000
samples tested, which will form a substantial body of clinical evidence around the
Unyvero Solution and our Pneumonia Application.“

“While data analysis for the multicenter study will be ongoing for some time, we have
already seen some rather exciting case studies of patients who might have bene? ted
substantially from the rapid and comprehensive diagnostic solution offered by Curetis´
Unyvero Solution,” said Dr. Peter Keller of Friedrich-Schiller University in Jena.

“With the testing completed on beta-prototypes of the Unyvero systems, we are now
intrigued by the availability of fully CE-marked series-production instruments and look
forward to a growing body of clinical data. We will continue working with the Curetis
team to make the solution available to microbiologists and clinicians for routine use
and to the bene? t of our patients.”

About the Unyvero™ System

The CE-marked Unyvero™ System is a versatile hardware platform for the detection
of a broad panel of bacteria and antibiotic resistances from a single sample in one
run. It processes a disposable cartridge providing the necessary reagents to complete
the analysis from sample to result.

The platform enables the DNA-based testing of all clinically relevant samples in a
fully automated, unsupervised analysis process requiring only few, quick manual
preparation steps. The analysis thus can be performed with minimal operator time and
without the need of skilled staff or special infrastructure.

Thereby, clinically relevant information is available within about four hours to support
an informed therapy decision as early as possible.

Cartridges for additional indications, such as blood stream infections and tuberculosis,
are in preparation.

About Curetis AG

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on
the development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG will
enable rapid multiparameter pathogen and antibiotic resistance detection in only a few
hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised total funds of over € 36.6 million (~ USD 50 million). The
company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed
collaboration agreements with Heraeus Medical, Sano? Pasteur and Cempra Inc. as
well as several international distribution agreements